Elena Ceccacci

This paper shows that extending G1 phase in cancer cells creates a therapeutic window for epigenetic drugs, with LSD1 inhibition and CDK4/6 inhibition working synergistically to induce differentiation and improve survival in AML models.

This paper identifies S166 phosphorylation on LSD1 as a regulatory switch that controls gene activation, chromatin remodeling, and tumor microenvironment in non-hormonal cancer cells.

This paper introduces an automated method for analyzing the cell cycle in both adherent and non-adherent cells using machine learning, validated in AML cell lines and drug response testing.

This study shows that inhibiting LSD1 enhances CD8+ T cell function in adoptive T cell therapy, leading to improved antitumor immunity and synergistic effects with anti-PDL1 therapy.

The paper generates a refined single-cell landscape of haematopoiesis in the mouse foetal liver using scRNA-seq, identifying new cell populations and transcriptional dynamics.

The paper shows KIT is required for fetal liver erythropoiesis but not for yolk sac endoHT or brain angiogenesis.